Development of the First Two-Pore Domain Potassium Channel TWIK-Related K+Channel 1-Selective Agonist Possessing in Vivo Antinociceptive Activity

Journal of Medicinal Chemistry
2017.0

Abstract

The TWIK-related K+ channel, TREK-1, has recently emerged as an attractive therapeutic target for the development of a novel class of analgesic drugs, suggesting that activation of TREK-1 could result in pain inhibition. Here, we report the synthesis of a series of substituted acrylic acids (1-54) based on our previous work with caffeate esters. The analogues were evaluated for their ability to modulate TREK-1 channel by electrophysiology and for their in vivo antinociceptive activity (acetic acid-induced writhing and hot plate assays), leading to the identification of a series of novel molecules able to activate TREK-1 and displaying potent antinociceptive activity in vivo. Furyl analogue 36 is the most promising of the series.

Knowledge Graph

Similar Paper

Development of the First Two-Pore Domain Potassium Channel TWIK-Related K<sup>+</sup>Channel 1-Selective Agonist Possessing in Vivo Antinociceptive Activity
Journal of Medicinal Chemistry 2017.0
TREK Channel Family Activator with a Well-Defined Structure–Activation Relationship for Pain and Neurogenic Inflammation
Journal of Medicinal Chemistry 2020.0
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K<sup>+</sup>Channel 1). A Novel Therapeutic Target?
Journal of Medicinal Chemistry 2016.0
Transient Receptor Potential Ankyrin 1 (TRPA1) Channel as Emerging Target for Novel Analgesics and Anti-Inflammatory Agents
Journal of Medicinal Chemistry 2010.0
Identification of a Potent Tryptophan-Based TRPM8 Antagonist With in Vivo Analgesic Activity
Journal of Medicinal Chemistry 2018.0
Kaurenoic Acid fromSphagneticola trilobataInhibits Inflammatory Pain: Effect on Cytokine Production and Activation of the NO–Cyclic GMP–Protein Kinase G–ATP-Sensitive Potassium Channel Signaling Pathway
Journal of Natural Products 2012.0
Synthesis of resveratrol derivatives as new analgesic drugs through desensitization of the TRPA1 receptor
Bioorganic &amp; Medicinal Chemistry Letters 2017.0
Synthesis and SAR of 4-aminocyclopentapyrrolidines as N-type Ca2+ channel blockers with analgesic activity
Bioorganic &amp; Medicinal Chemistry 2012.0
Optimization of a Pyrimidinone Series for Selective Inhibition of Ca<sup>2+</sup>/Calmodulin-Stimulated Adenylyl Cyclase 1 Activity for the Treatment of Chronic Pain
Journal of Medicinal Chemistry 2022.0
Novel amide derivatives of 1,3-dimethyl-2,6-dioxopurin-7-yl-alkylcarboxylic acids as multifunctional TRPA1 antagonists and PDE4/7 inhibitors: A new approach for the treatment of pain
European Journal of Medicinal Chemistry 2018.0